[go: up one dir, main page]

NO944018D0 - Behandling av makulær degenerasjon - Google Patents

Behandling av makulær degenerasjon

Info

Publication number
NO944018D0
NO944018D0 NO944018A NO944018A NO944018D0 NO 944018 D0 NO944018 D0 NO 944018D0 NO 944018 A NO944018 A NO 944018A NO 944018 A NO944018 A NO 944018A NO 944018 D0 NO944018 D0 NO 944018D0
Authority
NO
Norway
Prior art keywords
macular degeneration
treatment
disease
deprenyl
ameliorate
Prior art date
Application number
NO944018A
Other languages
English (en)
Other versions
NO944018L (no
Inventor
Barbara A Fries Hastings
Original Assignee
Somerset Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somerset Pharmaceuticals Inc filed Critical Somerset Pharmaceuticals Inc
Publication of NO944018D0 publication Critical patent/NO944018D0/no
Publication of NO944018L publication Critical patent/NO944018L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Semiconductor Lasers (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO944018A 1992-04-23 1994-10-21 Behandling av makulær degenerasjon NO944018L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/872,839 US5242950A (en) 1992-04-23 1992-04-23 Treatment of macular degeneration
PCT/US1993/003862 WO1993021894A2 (en) 1992-04-23 1993-04-23 Treatment of macular degeneration

Publications (2)

Publication Number Publication Date
NO944018D0 true NO944018D0 (no) 1994-10-21
NO944018L NO944018L (no) 1994-10-21

Family

ID=25360402

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944018A NO944018L (no) 1992-04-23 1994-10-21 Behandling av makulær degenerasjon

Country Status (14)

Country Link
US (1) US5242950A (no)
EP (1) EP0637238B1 (no)
JP (1) JP2669721B2 (no)
AT (1) ATE175348T1 (no)
AU (1) AU679679B2 (no)
BR (1) BR9306283A (no)
CA (1) CA2133998C (no)
DE (1) DE69322957T2 (no)
DK (1) DK0637238T3 (no)
ES (1) ES2127819T3 (no)
GR (1) GR3029670T3 (no)
HU (1) HU224917B1 (no)
NO (1) NO944018L (no)
WO (1) WO1993021894A2 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025380A (en) * 1990-12-14 2000-02-15 Smithkline Beecham Plc Medicament
US5783606A (en) * 1995-02-10 1998-07-21 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6033682A (en) * 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
WO1996024346A1 (en) 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
CA2223588C (en) * 1995-06-07 2004-01-06 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US5827652A (en) 1995-10-31 1998-10-27 Applied Food Biotechnology, Inc. Zeaxanthin formulations for human ingestion
CN1207675A (zh) * 1995-11-06 1999-02-10 萨默塞特药品有限公司 丙炔苯丙胺的经颊和舌下给药法
EP1063981B1 (en) 1998-03-16 2002-08-14 Somerset Pharmaceuticals, Inc. Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
US7691406B2 (en) * 2000-10-27 2010-04-06 ZeaVision LLC. Zeaxanthin formulations for human ingestion
AU2002354017B2 (en) 2001-11-05 2007-08-16 Krele Pharmaceuticals, Inc. Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US8088363B2 (en) 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
WO2004041151A2 (en) * 2002-11-07 2004-05-21 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20040180090A1 (en) * 2003-03-12 2004-09-16 Demarco Peter Treatment of macular degeneration
CA2523567A1 (en) * 2003-04-25 2004-11-11 Indevus Pharmaceuticals, Inc. Method for promoting uninterrupted sleep by administration of trospium chloride
US20070082066A1 (en) * 2003-05-07 2007-04-12 Gierhart Dennis L Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity
US7941211B2 (en) * 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
EP1686973A4 (en) 2003-11-25 2009-03-25 Technion Res & Dev Foundation COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISEASES
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
EP3381446A1 (en) 2004-10-29 2018-10-03 The Regents of The University of California Porous photonic crystals for drug delivery to the eye
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
BRPI0714985A2 (pt) * 2006-07-28 2013-07-30 Alcon Res Ltd inibidores de monoamina oxidase éteis para tratar distérbios da retina externa
AU2008275181B2 (en) 2007-07-10 2014-06-26 The Regents Of The University Of California Materials and methods for delivering compositions to selected tissues
RU2734632C2 (ru) 2010-02-03 2020-10-21 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
US9394369B2 (en) 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
WO2017008059A1 (en) 2015-07-09 2017-01-12 The Regents Of The University Of California Fusogenic liposome-coated porous silicon nanoparticles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4868218A (en) * 1987-08-18 1989-09-19 Buyske Donald A Method of treating depression
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same

Also Published As

Publication number Publication date
JP2669721B2 (ja) 1997-10-29
DE69322957D1 (de) 1999-02-18
HU9403052D0 (en) 1994-12-28
AU4033993A (en) 1993-11-29
AU679679B2 (en) 1997-07-10
GR3029670T3 (en) 1999-06-30
ATE175348T1 (de) 1999-01-15
HUT72295A (en) 1996-04-29
JPH07505906A (ja) 1995-06-29
CA2133998C (en) 2006-03-21
WO1993021894A2 (en) 1993-11-11
ES2127819T3 (es) 1999-05-01
NO944018L (no) 1994-10-21
WO1993021894A3 (en) 1994-01-20
US5242950A (en) 1993-09-07
EP0637238A1 (en) 1995-02-08
HU224917B1 (en) 2006-04-28
CA2133998A1 (en) 1993-11-11
DK0637238T3 (da) 1999-08-30
DE69322957T2 (de) 1999-07-01
EP0637238B1 (en) 1999-01-07
BR9306283A (pt) 1998-06-30

Similar Documents

Publication Publication Date Title
NO944018D0 (no) Behandling av makulær degenerasjon
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
ATE207355T1 (de) Behandlung von hyperproliferativen gefässerkrankungen
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
DE69327328D1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
MY104521A (en) Treatment of depression.
ATE131055T1 (de) Behandlung von kognitiven störungen.
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
CS22891A2 (en) Application of benzylphosphonic acid's derivatives for treatment of virusinduced diseases
ES2117008T3 (es) Metodo de tratamiento con amperozida de la esquizofrenia resistente a la terapia.
EA200200559A1 (ru) Способ лечения и профилактики нейродегенеративных состояний
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
RU93046326A (ru) Способ лечения медикаментозных эзофаго-гингиво-стоматитов
RU1821745C (en) Method for prognosticating effectiveness of efferent therapeutic treatment of patients suffering from immunocomplex diseases
ATE316373T1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
IL90059A0 (en) Paromomycin or its derivatives or salts thereof for treatment of human parasitic diseases
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
DK8893D0 (da) Medicament for treatment or prevention of disease